Through an agreement, Adhera has exclusive worldwide rights to develop MLR-1023 for Type 1 diabetes, Non-Alcoholic Steatohepatitis, Pulmonary Inflammation. Adhera will utilize extensive clinical data on MLR-1023 to move directly into Phase 2 clinical trials for these indications.
There is nothing anyone can do to prevent T1D, as presently, there is no known cure.
Annual direct medical expenses and indirect costs such as lost income for T1D amount to $14.4 billion, with 264,000 new cases diagnosed in the U.S. annually.
There is nothing anyone can do to prevent T1D, as presently, there is no known cure.
Annual direct medical expenses and indirect costs such as lost income for T1D amount to $14.4 billion, with 264,000 new cases diagnosed in the U.S. annually.
There is nothing anyone can do to prevent T1D, as presently, there is no known cure.
Annual direct medical expenses and indirect costs such as lost income for T1D amount to $14.4 billion, with 264,000 new cases diagnosed in the U.S. annually.
Donec ac tempor lacus, et sagittis felis. Donec ac turpis nisl. Fusce quis ipsum nunc. Aenean dignissim elementum magna quis condimentum. Phasellus lacinia ipsum et nibh scelerisque, vitae condimentum risus sagittis. Cras sed urna felis. Morbi eget malesuada ipsum, accumsan tristique sem. Nam laoreet lorem eu nisi ullamcorper, ac finibus lorem facilisis. Curabitur sed euismod elit, eget suscipit turpis. Fusce at scelerisque nunc, non mollis dui.
Manufacturing of MLR-1019 underway for Phase 2a trial
Pre-IND engagement with FDA, DEA, European consultants, and specialty CROs
Registration records exist for mesocarb in Bulgaria, Romania, and Moldova, allowing for direct filing for Clinical Trial Approval (CTAs) in those countries
Commitment from leading U.S. KOLs to actively spend time in E.U. for site selection & site training
Our full presentation contains in depth drug and market information. Get it now and have chat with our Investor Relations department to answer all your questions.
